[go: up one dir, main page]

WO2003106624A3 - Gene lie au cancer utilise comme cible en chimiotherapie - Google Patents

Gene lie au cancer utilise comme cible en chimiotherapie Download PDF

Info

Publication number
WO2003106624A3
WO2003106624A3 PCT/US2003/018431 US0318431W WO03106624A3 WO 2003106624 A3 WO2003106624 A3 WO 2003106624A3 US 0318431 W US0318431 W US 0318431W WO 03106624 A3 WO03106624 A3 WO 03106624A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
target
methods
chemotherapy
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/018431
Other languages
English (en)
Other versions
WO2003106624A2 (fr
Inventor
Krista Evans
Reinhard Ebner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clinical Data Inc
Original Assignee
Avalon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalon Pharmaceuticals Inc filed Critical Avalon Pharmaceuticals Inc
Priority to AU2003245448A priority Critical patent/AU2003245448A1/en
Publication of WO2003106624A2 publication Critical patent/WO2003106624A2/fr
Publication of WO2003106624A3 publication Critical patent/WO2003106624A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention porte sur des séquences de gènes liées au cancer et sur des séquences dérivées d'amino-acides, ainsi que sur des procédés de test d'agents antitumoraux puissants sur la base de la modulation d'expression des gènes liés au cancer. L'invention porte également sur des anticorps qui réagissent aux polypeptides décrits, et sur des procédés d'utilisation de ces anticorps en vue de traiter des maladies cancéreuses, l'anticorps étant utilisé, par exemple, pour cibler des cellules cancéreuses in vivo afin d'y administrer des agents thérapeutiques. L'invention porte encore sur des méthodes de diagnostic utilisant les séquences de gènes.
PCT/US2003/018431 2002-06-13 2003-06-11 Gene lie au cancer utilise comme cible en chimiotherapie Ceased WO2003106624A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003245448A AU2003245448A1 (en) 2002-06-13 2003-06-11 Cancer-linked gene as target for chemotherapy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38867202P 2002-06-13 2002-06-13
US60/388,672 2002-06-13
US39796602P 2002-07-23 2002-07-23
US60/397,966 2002-07-23

Publications (2)

Publication Number Publication Date
WO2003106624A2 WO2003106624A2 (fr) 2003-12-24
WO2003106624A3 true WO2003106624A3 (fr) 2004-12-09

Family

ID=29740051

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/018431 Ceased WO2003106624A2 (fr) 2002-06-13 2003-06-11 Gene lie au cancer utilise comme cible en chimiotherapie

Country Status (2)

Country Link
AU (1) AU2003245448A1 (fr)
WO (1) WO2003106624A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876996A (en) * 1997-07-25 1999-03-02 Incyte Pharmaceuticals, Inc. Human S-adenosyl-L-methionine methyltransferase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876996A (en) * 1997-07-25 1999-03-02 Incyte Pharmaceuticals, Inc. Human S-adenosyl-L-methionine methyltransferase

Also Published As

Publication number Publication date
WO2003106624A2 (fr) 2003-12-24
AU2003245448A8 (en) 2003-12-31
AU2003245448A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
WO2003104399A3 (fr) Gene lie au cancer servant de cible en chimiotherapie
WO2003105758A3 (fr) Gene lie au cancer utilise comme cible pour la chimiotherapie
MA42935B1 (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
Felices et al. Notch signaling at later stages of NK cell development enhances KIR expression and functional maturation
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
PT1512014E (pt) Método de identificação de alo-antigénios e sua utilização para terapia de cancro e transplante
MA43457A1 (fr) Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers
WO2003097803A3 (fr) Gene lie au cancer utilise comme cible pour la chimiotherapie
WO2003101400A3 (fr) Gene lie au cancer comme cible de chimiotherapie
MA43090A1 (fr) Peptides, combinaisons de peptides et médicaments basés sur les cellules pour l'immunothérapie contre le cancer de la vessie urinaire et d'autres cancers
ATE403680T1 (de) Herstellung tetravalenter antikörper
BG101077A (bg) Пептиди
WO2004065547A3 (fr) Antigene associe au cancer du pancreas, anticorps correspondant et methodes de diagnostic et de traitement
EP1896582A4 (fr) Anticorps monoclonaux humains pour mort programmée 1 (mp-1) et procédés pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associés à d'autres immunothérapies
MA31225B1 (fr) Anticorps neutralisants des cytomegalovirus humains et leur utilisation
Goldstein et al. Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma
Oh et al. Direct regulation of IL-2 by curcumin
DE60137949D1 (de) Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs
WO2003106624A3 (fr) Gene lie au cancer utilise comme cible en chimiotherapie
ATE431742T1 (de) Modifizierte zytokine für krebs therapie
MX2025004652A (es) Conjugados de farmaco-anticuerpo del cumulo de diferenciacion (cd70) y metodos de uso de los mismos
DK0996636T3 (da) HA-1-antigenet
KR960704539A (ko) 단백질 키나아제 c 활성화제, 및 세포 항원 발현 감소를 위한 그의 용도
WO2003104419A3 (fr) Gene lie au cancer utilise en tant que cible pour la chimiotherapie
WO2003104404A8 (fr) Gène lié au cancer servant de cible en chimiothérapie

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP